AMGN · 10-Q · 2026Q2 · Full report

Stock Repurchase Program

AMGEN INC · 2026-08-05 · Importance 44 · Surprise 24

Amgen did not repurchase shares under its stock repurchase program during the six months ended June 30, 2026 or the comparable 2025 period. The company had $6.8 billion of remaining repurchase authorization at June 30, 2026. Common shares outstanding increased to 540.6 million from 538.8 million at December 31, 2025, primarily reflecting equity-award issuances. The lack of buybacks contrasts with $2.720 billion of dividends paid during the first six months of 2026.

Key facts

• During the six months ended June 30, 2026, we did not repurchase shares under our stock repurchase program and as of June 30, 2026, $6.8 billion of authorization remained available under the stock repurchase program. source
• During the six months ended June 30, 2026 we did not repurchase shares under our stock repurchase program and $6.8 billion of authorization remained available under the stock repurchase program as of June 30, 2026 source